Abstract
Genetic factors are involved in the aetiology of dementias. Three genes have been identified which, when mutated, cause Familial Alzheimer disease (FAD): the presenilin-1 (PS1), the presenilin-2 (PS2) and the amyloid precursor protein (APP) genes. Together, these mutations are responsible for 30-50% of the cases with autosomal dominant Alzheimer disease (AD), and for about 5% of all AD cases. While over 130 mutations have been identified in PS1, mutations in PS2 and APP are rarer, since only 10 and 22 mutations, respectively, have been found in these FAD genes. Instead, mutations in the MAPT gene were associated with Familial Frontotemporal dementia (FFTD) linked to chromosome 17 (FTDP-17). Frontotemporal dementia (FTD) can occur in a sporadic form, but in 30-50% of cases there is a positive family history of dementia. In this study, we determined the spectrum of mutations and the relative contribution of the above mentioned four genes in our Italian clinical series of patients with a positive family history of dementia.
Keywords: alzheimer disease, frontotemporal dementia, ps1, ps2, app, mapt, mutations, prevalence
Current Alzheimer Research
Title: Prevalence of Pathogenic Mutations in an Italian Clinical Series of Patients with Familial Dementia
Volume: 1 Issue: 3
Author(s): S. Signorini, R. Ghidoni, L. Barbiero, L. Benussi and G. Binetti
Affiliation:
Keywords: alzheimer disease, frontotemporal dementia, ps1, ps2, app, mapt, mutations, prevalence
Abstract: Genetic factors are involved in the aetiology of dementias. Three genes have been identified which, when mutated, cause Familial Alzheimer disease (FAD): the presenilin-1 (PS1), the presenilin-2 (PS2) and the amyloid precursor protein (APP) genes. Together, these mutations are responsible for 30-50% of the cases with autosomal dominant Alzheimer disease (AD), and for about 5% of all AD cases. While over 130 mutations have been identified in PS1, mutations in PS2 and APP are rarer, since only 10 and 22 mutations, respectively, have been found in these FAD genes. Instead, mutations in the MAPT gene were associated with Familial Frontotemporal dementia (FFTD) linked to chromosome 17 (FTDP-17). Frontotemporal dementia (FTD) can occur in a sporadic form, but in 30-50% of cases there is a positive family history of dementia. In this study, we determined the spectrum of mutations and the relative contribution of the above mentioned four genes in our Italian clinical series of patients with a positive family history of dementia.
Export Options
About this article
Cite this article as:
Signorini S., Ghidoni R., Barbiero L., Benussi L. and Binetti G., Prevalence of Pathogenic Mutations in an Italian Clinical Series of Patients with Familial Dementia, Current Alzheimer Research 2004; 1 (3) . https://dx.doi.org/10.2174/1567205043332108
DOI https://dx.doi.org/10.2174/1567205043332108 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Complex Actions of Statins in Brain and their Relevance for Alzheimer`s Disease Treatment: An Analytical Review
Current Alzheimer Research Inappropriate Drug Use in People with Cognitive Impairment and Dementia: A Systematic Review
Current Clinical Pharmacology The Endocannabinoid System and Huntingtons Disease
Current Drug Targets - CNS & Neurological Disorders Exercise Prescription for Post-Menopausal Women with Obesity
Current Women`s Health Reviews Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients
Current Vascular Pharmacology Variability in Individual Responsiveness to Aspirin: Clinical Implications and Treatment
Cardiovascular & Hematological Disorders-Drug Targets Cerebrovascular Damage as a Cause for Alzheimers Disease
Current Neurovascular Research Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Chest Pain, Panic Disorder and Coronary Artery Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways
Current Genomics Drug Targeting to the Brain - A Review
Current Nanoscience A Novel Prescription for Alzheimer’s Disease: Targeting Hypercoagulable States
Current Neurovascular Research Pharmacological Management of Psychosis in Parkinson Disease: A Review
Current Drug Therapy Approaches to a Multitargeting Drug Development: First Profiled 3- Ethoxycarbonyl-1-aza-9-oxafluorenes Representing a Perspective Compound Class Targeting Alzheimer Disease Relevant Kinases CDK1, CDK5 and GSK-3β
Medicinal Chemistry Amyloid-β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer’s Diseases
Current Alzheimer Research Development and Validation of a Fluorescence-Based HTS Assay for the Identification of P/Q-Type Calcium Channel Blockers
Combinatorial Chemistry & High Throughput Screening Relevant Modulation by Ferrous Ions of N-Methyl-D-Aspartate Receptors in Ischemic Brain Injuries
Current Neurovascular Research